Sodium cromoglicate inhalant - Patara Pharma

Drug Profile

Sodium cromoglicate inhalant - Patara Pharma

Alternative Names: Cromolyn sodium - Patara Pharma; Disodium cromoglicate; Inhaled sodium cromoglycate - Patara Pharma; PA-101; PA-101B

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Patara Pharma
  • Class Antiallergics; Antiasthmatics; Antitussives; Benzopyrans; Chromones; Nootropics; Small molecules
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cough; Pruritus; Systemic mastocytosis

Most Recent Events

  • 01 Dec 2016 Patara Pharma completes a phase II trial for Pruritus (Treatment-experienced) in USA (Inhalation) (NCT02696499)
  • 07 Sep 2016 Efficacy and adverse events data from a phase II trial in Cough (in patients with idiopathic pulmonary fibrosis) presented at the European Respiratory Society International Congress (ERS-2016)
  • 07 Sep 2016 Patara Pharma plans a phase IIb trial in Cough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top